AMENDMENTS TO THE CLAIMS

1-5. **(Cancelled)**

6. **(Currently Amended)** A composition for oral administration~~, wherein a base~~ comprising an enteric film-coated granule ~~containing~~,

wherein the granule comprises an alkylenedioxybenzene derivative represented by the general formula (I):



(I)

~~(~~wherein m represents an integer of 2 to 5, and n represents an integer of 1 to 3~~)~~,
or an acid addition salt thereof,

which is dispersed in a matrix ~~containing~~ comprising one or more waxes, and ~~an excipient is coated with an~~

wherein the enteric film coating comprises a copolymer selected from the group consisting of methacrylic acid copolymer LD, methacrylic acid copolymer L, methacrylic acid copolymer S, and combinations thereof.

7. **(Currently Amended)** The composition for oral administration according to claim 6, wherein ~~an amount of waxes is 5 to 70%~~ the granule comprises 5 to 70% by weight ~~relative to the base granule~~ of the one or more waxes.

8. **(Cancelled)**

9. **(Currently Amended)** A capsule, which is filled with ~~containing an alkylenedioxybenzene derivative or an acid addition salt thereof, comprising~~ the composition for oral administration

according to claim ~~1 filled therein~~6.

10. **(Currently Amended)** A process for preparing a composition for oral administration, comprising kneading an alkylenedioxybenzene derivative represented by the general formula (I):



(I)

~~(~~wherein m represents an integer of 2 to 5, and n represents an integer of 1 to 3~~)~~,
or an acid addition salt thereof,

which is dispersed in a matrix comprising one or more waxes, ~~and an excipient~~ to obtain a granule, and

coating the granule with an enteric film comprising a copolymer selected from the group consisting of methacrylic acid copolymer LD, methacrylic acid copolymer L, methacrylic acid copolymer S, and combinations thereof.

11. **(Currently Amended)** ~~A~~ The composition
for oral administration~~, wherein a pharmaceutically active substance is an alkylenedioxybenzene derivative represented by general formula (I):~~



(I)

~~(wherein m represents an integer of 2 to 5, and n represents an integer of 1 to 3) or an acid addition salt thereof, and a time for releasing~~ according to claim 6, which releases at least 80% of ~~a~~ its initial content of ~~the pharmaceutically active substance is~~ the

alkylenedioxybenzene derivative or the acid addition salt thereof within about 2 to about 24 hours when tested at 100 rotations per minute using 900 ml of a hydrochloric acid/trisodium phosphate buffer (pH 6.8) as a test solution according to a basket method (USP dissolution test first method).

12. **(Currently amended)** The composition for oral administration according to claim ~~1~~6, wherein the alkylenedioxybenzene derivative or the acid addition salt thereof is 5-[3-[[(2S)-1,4-benzodioxan-2-ylmethyl]amino]propoxy]-1,3-benzodioxole hydrochloride.

13-20. **(Cancelled)**

21. **(New)** The composition for oral administration according to claim 6, wherein the one or more waxes are selected from the group consisting of shellac, gelatin, hydrogenated beef tallow, hydrogenated castor oil, hydrogenated cottonseed oil, hydrogenated soybean oil, stearic acid, palmitic acid, alminium monostearate, glyceryl mono- or dipalmitate, glyceryl mono-, di- or tristearate, cetyl alcohol, stearyl alcohol, myristyl alcohol, 12-hydroxystearyl alcohol, beewax, Japan wax, carnauba wax, paraffin wax, whale wax, and synthetic wax.

22. **(New)** The composition for oral administration according to claim 6, wherein the granule comprises 20 to 40% by weight of the enteric film coating.

23. **(New)** The composition for oral administration according to claim 6, wherein the granule comprises 20 to 50% by weight of the one or more waxes.